Pharmacokinetics, by the label

GLP-1 Half-Life by Label: How Long Each Medication Lasts, and Why It Matters

A half-life is the time it takes for the amount of a drug in the blood to fall by half. For GLP-1 medicines it ranges from about 13 hours to about a week, and that single number explains a lot: why some are daily and others weekly, why levels build over the first month, why a label asks for a two-month gap before a planned pregnancy, and why missed-dose rules differ so much between products. This page quotes the elimination half-life from Section 12.3 of each FDA label, marks the one product whose label gives none, and explains what the figures do and do not tell you. It gives no dosing instructions.

· Educational content — not medically reviewed

The short answer

GLP-1 half-life ranges from hours to about a week on the FDA labels: approximately 13 hours for liraglutide (Victoza), 29 to 49 hours for orforglipron (Foundayo), about 5 days for dulaglutide (Trulicity), 5 to 6 days for tirzepatide (Zepbound), and about 1 week for semaglutide, injected or as a tablet. The Bydureon BCise label states no single half-life. After roughly five half-lives, most of a drug is gone.

A woman by a window looking at a large paper sheet on the wall with one smooth green curve that rises and slowly falls, with an hourglass and a plant on the desk beside her.

Key takeaways

  • Semaglutide, injected or as a tablet: approximately 1 week, and present in the circulation for about 5 to 7 weeks after the last dose (Wegovy label, DailyMed version of 30 June 2026).
  • Tirzepatide: approximately 5 to 6 days (Zepbound label, DailyMed version of 2 September 2026). Dulaglutide: approximately 5 days (Trulicity label, 10 August 2026). Liraglutide: approximately 13 hours (Victoza label, 17 November 2025).
  • Orforglipron (Foundayo): approximately 29 to 49 hours after an oral dose (Foundayo label, 13 August 2026). Exenatide extended-release (Bydureon BCise): the label states no single half-life, only that levels fall below quantifiable about 10 weeks after stopping.
  • General pharmacology rule of thumb, not a label figure: after about five half-lives roughly 97% of a drug is gone, and with steady dosing levels take about four to five half-lives to plateau.
  • Labels use half-life for pregnancy planning, overdose observation and missed-dose design, but no label turns it into a hold interval for surgery. Those decisions belong to your prescriber and anesthesia team.

From hours to a week

Native GLP-1 lasts 1.5 to 2 minutes in the blood, per the Victoza label. Every medicine on this page is engineered to resist that breakdown, which is how liraglutide reaches about 13 hours and semaglutide about a week.

Five half-lives, roughly gone

Each half-life halves what is left: 50%, 25%, 12.5%, 6.25%, about 3%. That arithmetic is why the Wegovy label says semaglutide stays in the circulation for 5 to 7 weeks after a one-week half-life.

Why weekly drugs are weekly

A half-life near a week lets one injection carry a whole week. A half-life of hours, as with liraglutide, needs a daily dose. Orforglipron sits in between and is taken daily as a tablet.

See the curve, not your level

Our medication level estimator and GLP-1 Tracker's Medication Level widget draw an educational curve from logged doses and label half-lives. It is an illustration, never a blood level or a dosing tool.

Every GLP-1 half-life, as the label states it

Every figure below comes from Section 12.3, Pharmacokinetics, of the product's FDA prescribing information as published on DailyMed, read on 9 November 2026. Where two brands share a molecule, the figure is the same molecule's; the per-product reference pages hold the full detail.

Semaglutide (Ozempic, Wegovy, Rybelsus, Ozempic tablets, Wegovy tablets). The Wegovy label, which covers both the injection and the tablets, states an elimination half-life of approximately 1 week and that semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable or oral dose. The label credits the long half-life mainly to albumin binding, which protects semaglutide from degradation and slows its clearance by the kidneys. The Ozempic reference page covers that label's slightly shorter five-week wording.

Tirzepatide (Mounjaro, Zepbound). The Zepbound label states an elimination half-life of approximately 5 to 6 days in people with overweight or obesity, including those with obstructive sleep apnea, and that steady-state concentrations were reached after 4 weeks of once-weekly dosing. It attributes the long half-life to a C20 fatty diacid that enables albumin binding. See the Zepbound reference page.

Liraglutide (Victoza, Saxenda). The Victoza label states an elimination half-life of approximately 13 hours after subcutaneous injection. See the Victoza reference page.

Dulaglutide (Trulicity). The Trulicity label states an elimination half-life of approximately 5 days, with steady state reached between 2 and 4 weeks of once-weekly dosing. See the Trulicity reference page.

Exenatide extended-release (Bydureon BCise). The last FDA label, revised May 2025 and published on the FDA's Drugs@FDA site, states no single elimination half-life for the extended-release product. It says concentrations rise gradually to about Week 10, when steady state was reached, and that about 10 weeks after stopping, levels generally fall below the minimum the assay can measure. The product is no longer marketed in the United States; the Bydureon BCise reference page explains the gap.

Orforglipron (Foundayo). The Foundayo label states an elimination half-life of approximately 29 to 49 hours after an oral dose, and steady state after approximately 1 week of once-daily dosing. See the Foundayo reference page.

Estimated medication level over ten weeks of weekly doses, with one missed weekSettles after about five half-livesMissed weekWeek 1Week 3Week 5Week 10Estimated level

Weekly dose

Illustrative shape for a weekly medication with a roughly one-week half-life. Each dose adds to what earlier doses left behind, so the level climbs for about five weeks and then settles. Not your level, and not dosing guidance.

What a half-life means in practice

A half-life is the time it takes for the concentration of a drug in the blood to fall by half once it is no longer being added. It is a population figure, an average from the people in the pharmacokinetic studies; your own body may run a little faster or slower.

The useful thing about a half-life is that it compounds. After one half-life, half the drug is left. After two, a quarter. After three, an eighth. After five, about 3%. That is the basis of a general pharmacology rule of thumb: a drug is considered mostly cleared after about five half-lives. This rule is textbook pharmacology, not a statement from any of the labels, and it is an approximation.

Applied to the label figures, the arithmetic gives these rough clearance times: liraglutide, about three days; orforglipron, roughly six to ten days, depending on where in its range you sit; dulaglutide and tirzepatide, roughly four weeks; semaglutide, about five weeks. Where a label gives its own figure, the label wins. The Wegovy label's 5 to 7 weeks for semaglutide is a little longer than the simple rule suggests, and the Bydureon BCise label's roughly 10 weeks reflects an extended-release depot rather than a simple half-life.

The same compounding works in reverse while you are taking a medication. Each dose lands on top of what is left of the previous ones, so levels climb over several doses before they settle into a repeating pattern called steady state. The rule of thumb is about four to five half-lives to get there, which matches the labels: about 1 week for orforglipron, 2 to 4 weeks for dulaglutide, 4 weeks for tirzepatide. That build-up is one reason the first weeks on a weekly medication can feel different from later weeks even before any dose change.

Why weekly drugs are weekly and daily drugs are daily

Native GLP-1, the hormone your gut makes after a meal, has a half-life of 1.5 to 2 minutes, according to the Victoza label, because enzymes called DPP-4 and neutral endopeptidases break it down almost immediately. A medicine that lasted two minutes would be useless, so every product on this page is a modified molecule designed to survive.

How well it survives decides the schedule. Liraglutide, at about 13 hours, would fall to a fraction of its level within a couple of days, so it is a once-daily injection. Semaglutide, dulaglutide and tirzepatide, at roughly five days to a week, lose only about half their level between weekly doses, so one injection can carry seven days. That is the whole reason a weekly shot is possible, and the reason the weekly products were developed.

The oral products show the other side of the trade. Oral semaglutide keeps the one-week half-life, yet it is a daily tablet, because each tablet delivers only a percent or two of its dose and a daily dose builds the level up gradually. Orforglipron, at 29 to 49 hours, is long enough that levels do not swing wildly between doses but short enough that once daily is the natural rhythm.

None of this says one schedule is better. A short half-life means a missed dose shows up quickly and also fades quickly. A long one smooths over a late dose but takes weeks to wash out. Which suits a person is a clinical choice made with a prescriber, not something a half-life table decides.

How the labels themselves use half-life

Half-life appears in the labels in more places than Section 12.3, and reading those passages shows what the number is for.

Pregnancy planning. The Wegovy label advises discontinuing at least 2 months before a planned pregnancy for patients receiving it for weight reduction or cardiovascular risk reduction, explicitly to account for the long half-life of semaglutide. Eight weeks is comfortably more than five one-week half-lives. Our pregnancy, breastfeeding and fertility label reference sets out each label's wording.

Overdose. The Zepbound and Foundayo labels both say that observation and treatment after an overdose may need to take the half-life into account; the Wegovy label speaks of a prolonged period of observation, taking into account a half-life of approximately 1 week.

Missed doses. Every label has its own missed-dose section, and the rules differ between products, partly because the half-lives differ: a weekly injection and a daily tablet cannot share one rule. We deliberately do not restate those rules, because a rule copied from another product can be the wrong one for yours. Read your own product's section or ask your pharmacist; our missed GLP-1 dose page covers what to record.

Surgery and procedures. Every label in this class now warns about pulmonary aspiration under general anesthesia or deep sedation and tells patients to inform their providers of planned procedures. None of them converts the half-life into a hold interval. Whether and when to pause is decided by the anesthesia team and prescriber using professional-society guidance, which our surgery and endoscopy page summarises without publishing an interval.

What a half-life cannot tell you

A half-life is easy to over-read, so it is worth being explicit about its limits.

It is not your number. The label figure is an average from study populations. Body weight, kidney function, injection site and ordinary biological variation all move individual results, and some labels give a range for exactly that reason.

It is not a measure of effect. Appetite, nausea and blood sugar do not rise and fall in a simple line with blood concentration, and the labels note that gastric-emptying effects are largest after the first dose and diminish over time even as levels build.

It is not a dosing tool. Knowing that semaglutide halves in about a week does not tell anyone whether to take a late dose, skip one, move an injection day or restart. Those are label instructions applied by a prescriber to your history. And it is not a safety clock for side effects: a reaction can persist or appear after a drug has largely cleared.

What a half-life is good for is understanding. It explains why the first month feels different, why stopping does not end the effect overnight, and why your prescriber asks about the date of your last dose before a procedure. That is useful context to bring to an appointment, not a basis for changing anything on your own.

Seeing a half-life curve against your own log

If you want to see what a half-life looks like, our free medication level estimator draws an educational curve from a dose history and a published half-life figure, so the build-up to steady state and the slow tail after a last dose are visible rather than abstract. GLP-1 Tracker, the free iPhone and iPad app this site belongs to, does the same thing from the doses you log, and offers it as a Medication Level home-screen widget.

Both are teaching illustrations. They use population figures of the kind quoted on this page, not measurements from you. They cannot account for your weight, kidney function, absorption or adherence, and the curve is not a blood level, not a clinical reading and not something to show an anesthesia team as evidence of anything. The app is a logging layer: it records the doses you enter, with their dates, and draws a picture from them. It never suggests taking, skipping, moving or restarting a dose.

The honest use of the curve is the one the labels support: understanding why the first weeks feel the way they do, and having an accurate record of when each dose was taken for the person who does make the decisions.

Frequently asked questions

What is the half-life of semaglutide?

Approximately 1 week, for both the injection and the tablets. The Wegovy label adds that semaglutide stays in the circulation for about 5 to 7 weeks after the last injectable or oral dose. Ozempic, Wegovy, Rybelsus and the semaglutide tablets all share the molecule.

What is the half-life of orforglipron (Foundayo)?

The Foundayo label states approximately 29 to 49 hours after an oral dose, with steady state after about 1 week of once-daily dosing. By the five-half-life rule of thumb, most of it would be cleared within roughly six to ten days, though the label itself gives no clearance time.

What is the half-life of tirzepatide?

The Zepbound label states approximately 5 to 6 days in adults with overweight or obesity, with steady state after 4 weeks of once-weekly dosing. Mounjaro is the same molecule. Five half-lives comes to roughly four weeks, a rule-of-thumb estimate rather than a label figure.

How long does a GLP-1 stay in your system?

It depends on the molecule. Using the general five-half-life rule: about three days for liraglutide, six to ten days for orforglipron, roughly four weeks for dulaglutide and tirzepatide, about five weeks for semaglutide. The Wegovy label says 5 to 7 weeks; Bydureon BCise's label says about 10 weeks.

Why is Ozempic weekly but Victoza daily?

Half-life. Semaglutide's is about a week, so a weekly injection loses only about half its level before the next. Liraglutide's is about 13 hours per the Victoza label, so it would fall too far within a week and is injected daily.

Can I use the half-life to decide when to take a late dose?

No. Each label has its own missed-dose instruction, and applying it to your history is your prescriber's job. A half-life explains why those rules differ between products; it does not replace them.

Is the medication level in GLP-1 Tracker my real blood level?

No. It is an educational curve drawn from the doses you log and a published label half-life. It cannot account for your weight, kidney function or absorption, it is not a measurement, and it never suggests changing a dose.

Keep the dates the half-life depends on

GLP-1 Tracker logs every dose with its date and draws an educational medication-level curve from them. Free on iPhone and iPad, synced through your private iCloud.

This page is for general education only and is not medical advice, diagnosis or treatment. GLP-1 Tracker is a tracking tool, not a medical device. Always consult your healthcare provider about your medication, dosing and health decisions. Brand names are trademarks of their respective owners and are not affiliated with this app.